Biotricity (Biotricity) LT-Debt-to-Total-Asset : 2.27 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biotricity LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biotricity's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 2.27.

Biotricity's long-term debt to total assets ratio increased from Dec. 2022 (2.12) to Dec. 2023 (2.27). It may suggest that Biotricity is progressively becoming more dependent on debt to grow their business.

Biotricity LT-Debt-to-Total-Asset Historical Data

The historical data trend for Biotricity's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity LT-Debt-to-Total-Asset Chart

Biotricity Annual Data

Trend

Aug14

Aug15

Dec16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.08

0.82

2.22

Biotricity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															2.12	2.22	2.24	1.92	2.27

Biotricity LT-Debt-to-Total-Asset Calculation

Biotricity's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	14.436	/	6.511
	=	2.22

Biotricity's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	12.456	/	5.486
	=	2.27

Biotricity (NAS:BTCY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biotricity LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Biotricity's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotricity (Biotricity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

QB00:Germany

Address

275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065

Website

https://www.biotricity.com

Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.

Executives

Chester P White	director	447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon	director	1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq	director, 10 percent owner, officer: CEO and Chairman of the Board	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou	officer: Chief Financial Officer	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065